Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 1 Feb 2014

Corti Giampaolo, Salomoni Elena, Baragli Filippo

Abstract excerpt

The recent introduction of direct antiviral agents (DAAs) as a fundamental part of anti-hepatitis C virus (HCV) therapy has dramatically improved the possibility of cure for patients with genotype 1, but at the same time has increased the incidence of severe adverse events and the risk of reduced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anemia
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Injections, Subcutaneous

Share to Interferon-alpha

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 24246771
DOI: 10.1016/j.ijid.2013.09.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24246771-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.PMID 24246771Read ↗

Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Semantic proximity Read ↗

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.Semantic proximity Read ↗

Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.Semantic proximity Read ↗

Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.Semantic proximity Read ↗

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis.Semantic proximity Read ↗

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].Semantic proximity Read ↗

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Semantic proximity Read ↗

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.Semantic proximity Read ↗

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.Semantic proximity Read ↗

[Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1].Semantic proximity Read ↗

Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.